- Home
- ARBE vs IFRX Comparison
ARBE vs IFRX Comparison
Compare ARBE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- IFRX
- Stock Information
- Founded
- ARBE 2015
- IFRX 2007
- Country
- ARBE Israel
- IFRX Germany
- Employees
- ARBE N/A
- IFRX N/A
- Industry
- ARBE EDP Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARBE Technology
- IFRX Health Care
- Exchange
- ARBE Nasdaq
- IFRX Nasdaq
- Market Cap
- ARBE 161.8M
- IFRX 143.7M
- IPO Year
- ARBE N/A
- IFRX 2017
- Fundamental
- Price
- ARBE $1.70
- IFRX $2.24
- Analyst Decision
- ARBE Strong Buy
- IFRX Strong Buy
- Analyst Count
- ARBE 2
- IFRX 1
- Target Price
- ARBE $3.00
- IFRX $8.00
- AVG Volume (30 Days)
- ARBE 191.3K
- IFRX 401.6K
- Earning Date
- ARBE 11-27-2024
- IFRX 11-08-2024
- Dividend Yield
- ARBE N/A
- IFRX N/A
- EPS Growth
- ARBE N/A
- IFRX N/A
- EPS
- ARBE N/A
- IFRX N/A
- Revenue
- ARBE $1,016,000.00
- IFRX $187,930.00
- Revenue This Year
- ARBE $1.56
- IFRX $435.15
- Revenue Next Year
- ARBE $395.31
- IFRX $180.44
- P/E Ratio
- ARBE N/A
- IFRX N/A
- Revenue Growth
- ARBE N/A
- IFRX 177.12
- 52 Week Low
- ARBE $1.40
- IFRX $1.17
- 52 Week High
- ARBE $2.57
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ARBE 39.74
- IFRX 52.76
- Support Level
- ARBE $1.58
- IFRX $1.93
- Resistance Level
- ARBE $1.75
- IFRX $2.74
- Average True Range (ATR)
- ARBE 0.07
- IFRX 0.25
- MACD
- ARBE -0.01
- IFRX -0.06
- Stochastic Oscillator
- ARBE 20.50
- IFRX 34.88
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.